A Phase 2a Randomised, Double-Blind, Placebo-Controlled, 2-Period Crossover Study To Assess The Efficacy And Safety Of Mk952 In Patients With Alzheimer's Disease
Phase of Trial: Phase II
Latest Information Update: 28 Jul 2017
At a glance
- Drugs MK 0952 (Primary)
- Indications Alzheimer's disease; Dementia
- Focus Proof of concept; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 13 May 2016 Status changed from completed to discontinued.
- 20 Aug 2009 Additional lead trial centres identified as reported by United Kingdom Clinical Research Network record.
- 04 Mar 2009 New source identified and integrated (1087413 United Kingdom Clinical Research Network)